-

Bharat Rajagopal Joins Verily as Chief Revenue Officer

Former Microsoft life sciences commercial leader brings extensive experience advancing digital transformation across healthcare and technology

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verily, an Alphabet precision health technology company, today announced the appointment of Bharat Rajagopal as Chief Revenue Officer. Rajagopal will join Verily’s leadership team and be responsible for the strategy and execution of all commercial revenue generating activities, including driving sales, business development, partnerships, and customer success to advance precision health.

Rajagopal brings more than two decades of experience leading commercial growth and digital transformation at Microsoft. While at Microsoft, Rajagopal held a series of customer-facing leadership roles, most recently, serving as the General Manager of Microsoft’s U.S. Life Sciences and MedTech business. In this role, he led a team of sales, technical, and operational leaders and partnered with pharma, medtech, and life science organizations to advance their digital transformation efforts to bring life-saving therapies to market faster. Rajagopal also partnered with next generation healthcare startups to build and scale on the Microsoft cloud.

“Bharat is a distinguished commercial executive with extensive experience driving technology adoption for some of the most innovative organizations across healthcare,” said Stephen Gillett, Chief Executive Officer at Verily. “His leadership and expertise will be critical as we deepen and scale our customer relationships to deliver on the promise of precision health.”

Prior to his role as General Manager, Rajagopal served as Chief Operating Officer of Microsoft's Gulf Coast Enterprise & Partner Group. In this role, he drove significant enterprise software growth by enabling digital transformation for global customers in high tech, oil, and gas. In addition to his commercial leadership at Microsoft, Rajagopal frequently collaborates with external groups that set industry standards and remove barriers to the adoption of technology across life sciences.

“Over the last 20 years, my work has been focused on partnering with enterprises, including life sciences and medtech companies, to drive the adoption and use of transformative technologies,” said Bharat Rajagopal. “With the recent advances in AI, we have a generational opportunity to discover therapies never imagined before. I’m thrilled to continue my mission at Verily by partnering with organizations across the ecosystem to deliver new data, AI, and technology solutions that accelerate evidence generation and advance precision health.”

About Verily

Verily is an Alphabet health technology company focused on research, care, and health financing to deliver on the promise of precision health and help people live healthier lives. We are uniquely positioned at the intersection of technology, data science, and healthcare to create tools to accelerate evidence generation, products to enable more personalized care, and approaches to make costs more predictable. For more information, please visit: verily.com

Contacts

Steven Cooper
Head of Media Relations, Verily
sjcoop@verily.com

Verily


Release Versions

Contacts

Steven Cooper
Head of Media Relations, Verily
sjcoop@verily.com

More News From Verily

Verily Workbench Now Available on AWS

DALLAS--(BUSINESS WIRE)--Verily Health, a precision health AI company, announced at the 2026 AWS Life Sciences Symposium that Verily Workbench, Verily’s scalable trusted research environment (TRE) for biomedical data analysis and AI/ML development, is now generally available for organizations using Amazon Web Services (AWS). Workbench is an enterprise-grade TRE that enables researchers to co-analyze data where it lives, accelerating discovery through integrated AI tools with built-in healthcare...

Verily Secures $300 Million Investment to Advance its Precision Health AI Strategy

DALLAS--(BUSINESS WIRE)--Verily today announced a $300 million investment round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz and other investors, to advance the next phase of its precision health AI strategy. With this funding round, Alphabet will be a significant minority investor in Verily, while no longer having a controlling stake. “Today is an important step in our mission to bring the promise of precision health to everyone,” sai...

Verily Me Adds New Features, Offering a Safe and Private Space to Check Symptoms and Make Sense of Health

DALLAS--(BUSINESS WIRE)--Verily, a precision health AI company, today announced new features and the general availability of its consumer health app, Verily Me, following a successful beta phase. Verily Me is designed to close gaps in care by enabling access to personalized health recommendations from licensed providers based on individual medical history across clinicians and health systems. In addition, “Violet,” the AI companion available via Verily Me, provides 24/7 assistance to help users...
Back to Newsroom